Coalition to Cure Calpain 3 (C3) is pleased to announce the funding of a new research award to Dr. Meredith James and Professor Jordi Díaz-Manera of the John Walter Muscular Dystrophy Research Centre (JWMDRC) at Newcastle University. The project, titled
Publication shares development of new animal model of LGMD2A/R1
A paper published by Jason Berman, Children’s Hospital of Eastern Ontario Research Institute and University of Ottawa, along with colleagues from Dalhousie University, AGADA Biosciences, and Binghamton University – State University of New York, shares the development of a zebrafish
Sarepta Community Update on LGMD programs
Sarepta Therapeutics recently published a Community Letter to share updates on their limb-girdle muscular dystrophy gene therapy programs. Click here to access the letter on Sarepta’s website.
New research grant aims to improve genetic diagnoses in individuals with CAPN3 mutations
Coalition to Cure Calpain 3 (C3) is pleased to announce a research grant has been awarded to Dr. Svetlana Gorokhova, working together with Dr. Marc Bartoli in the Translational Neuromyology Team, Marseille Medical Genetics Institute at Aix Marseille University. The
C3’s Countdown to the New Year
In 2022, C3 … Announced 5 new research projects Generated 4 novel mouse models for preclinical drug testing Co-organized an EL-PFDD meeting where 300+ individuals with LGMD tuned in to share their perspectives on what it is like to live
C3 partners with 16 LGMD organizations in letter to FDA
Coalition to Cure Calpain 3 is proud to be one of 17 organizations dedicated to LGMD to have collaborated on a statement submitted to the Food and Drug Administration in conjunction with the recent Patient-Focused Drug Development Meeting Patient Perspectives
Our GIVING TUESDAY fundraiser starts NOW!
Champion Coalition to Cure Calpain 3’s cause to raise $50,000 for LGMD2A/R1 gene therapy research. Every dollar donated between now and December 1, 2022 will be matched, up to $25,000 by a family motivated to drive a gene therapy cure.
New LGMD2A/R1 Mice: Novel tools for drug development
Coalition to Cure Calpain 3 (C3) is excited to announce the generation of four mouse models of limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These mouse models were developed and characterized as part of a research grant from C3 to Dr.
Your voice made a difference!
THANK YOU to all those families impacted by limb-girdle muscular dystrophy types 2A, 2C, 2D, 2E, 2F, and 2I who made their voices heard at the LGMD EL-PFDD! Whether you were on camera, called in, submitted written comments, or participated
The LGMD EL-PFDD is just one week away!
Join us for this important LGMD event on September 23rd beginning at 10:00 AM EDT and make YOUR VOICE HEARD. Bookmark www.lgmdpfdd.com so you can view and participate live.
English
አማርኛ
العربية
简体中文
繁體中文
Dansk
Nederlands
Français
Deutsch
עִבְרִית
हिन्दी
Italiano
日本語
ភាសាខ្មែរ
한국어
كوردی
मराठी
Norsk bokmål
Polski
Português
ਪੰਜਾਬੀ
Русский
Español
Svenska
தமிழ்
తెలుగు
Türkçe